| Literature DB >> 27857944 |
James M Stringham1, Kevin J O'Brien2, Nicole T Stringham3.
Abstract
BACKGROUND: The so-called macular carotenoids (MC) lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) comprise the diet-derived macular pigment (MP). The purpose of this study was to determine effects of MC supplementation on the optical density of MP (MPOD), repeated-exposure photostress recovery (PSR), and disability glare (DG) thresholds.Entities:
Keywords: Disability glare; Lutein; Macular pigment; Mesozeaxanthin; Photostress recovery; Visual cycle; Visual performance; Zeaxanthin
Year: 2016 PMID: 27857944 PMCID: PMC5106769 DOI: 10.1186/s40662-016-0060-8
Source DB: PubMed Journal: Eye Vis (Lond) ISSN: 2326-0254
Baseline subject characteristics and main effects data
| Variable | Placebo ( | 12 mg ( | 24 mg ( |
|---|---|---|---|
| Age (years) | 21.71 ± 0.98 | 21.23 ± 0.95 | 21.68 ± 1.06 |
| Body mass index (kg/m2) | 25.87 ± 1.39 | 25.49 ± 1.54 | 25.72 ± 1.61 |
| Male | 4 (40 %) | 10 (42 %) | 13 (52 %) |
| Female | 6 (60 %) | 14 (58 %) | 12 (48 %) |
| Servings of fruits, vegetables/day | 1.78 ± 1.52 | 1.87 ± 1.34 | 1.77 ± 1.45 |
| Macular pigment optical density (0.5°) | 0.527 ± 0.213 | 0.488 ± 0.248 | 0.511 ± 0.202 |
| Disability glare (nominal intensity) | 88.42 ± 58.77 | 86.02 ± 55.23 | 91.8 ± 61.66 |
| Photostress recovery time (seconds) | 8.78 ± 5.96 | 9.11 ± 6.14 | 9.33 ± 6.39 |
Data for main effects at each measurement point in the trial, by group. Lutein and total zeaxanthin serum data are also included
| Group | Measure | Baseline | 6 months | 12 months |
|---|---|---|---|---|
| Placebo ( | MPOD | 0.527 ± 0.213 | 0.558 ± 0.222 | 0.564 ± 0.237 |
| Disability Glare | 88.42 ± 58.77 | 90.63 ± 57.47 | 91.96 ± 59.12 | |
| Photostress recovery (mins) | 8.78 ± 5.96 | 8.84 ± 6.12 | 8.71 ± 5.79 | |
| Serum L (μg/mL) | 0.34 ± 0.07 | 0.35 ± 0.07 | 0.34 ± 0.08 | |
| Serum total Z (μg/mL) | 0.13 ± 0.02 | 0.115 ± 0.03 | 0.125 ± 0.02 | |
| 12 mg ( | MPOD | 0.488 ± 0.248 | 0.586 ± 0.266* | 0.654 ± 0.282** |
| Disability Glare | 86.02 ± 55.23 | 113.55 ± 60.11* | 120.43 ± 64.52** | |
| Photostress recovery (mins) | 9.11 ± 6.14 | 7.65 ± 5.41* | 6.92 ± 5.09** | |
| Serum L (μg/mL) | 0.40 ± 0.08 | 2.24 ± 0.22* | 2.16 ± 0.20** | |
| Serum total Z (μg/mL) | 0.10 ± 0.014 | 0.29 ± 0.03* | 0.27 ± 0.03** | |
| 24 mg ( | MPOD | 0.511 ± 0.202 | 0.634 ± 0.271* | 0.685 ± 0.289** |
| Disability Glare | 91.8 ± 61.66 | 123.01 ± 67.43* | 128.52 ± 69.96** | |
| Photostress recovery (mins) | 9.33 ± 6.39 | 7.28 ± 5.86* | 6.99 ± 5.56* | |
| Serum L (μg/mL) | 0.33 ± 0.05 | 3.25 ± 0.27* | 3.29 ± 0.29** | |
| Serum total Z (μg/mL) | 0.13 ± 0.01 | 0.51 ± 0.06* | 0.53 ± 0.06** |
Based on repeated-measures ANOVA, single asterisk = significant difference from baseline and placebo (p < 0.05); double asterisk = significant difference from baseline, 6-month measure, and placebo (p < 0.05)
Fig. 1Percent change from baseline at 6 and 12 months for all outcome measures. Error bars are ± 1 SD. Single asterisk denotes significant difference from baseline and placebo (p < 0.05 level); double asterisk denotes significant differences from baseline, 6-month measure, and placebo (p < 0.05 level)
Fig. 2Glare ring intensity setting as a function of MPOD, at baseline
Fig. 3PSR time as a function of MPOD, at baseline
Fig. 4Change between baseline and 12 month measures in PSR time, as a function of the same change for DG thresholds. Symbol key for groups noted in legend
Fig. 5PSR “fatigue functions” at baseline for four subjects with different MPOD. Functions fit with B-spline interpolation. See text for explanation